Copy Link Print Information

Sunitinib

(別名: SU 11248)
108 Cited Publications
カスタマーレビュー

Based on 108 publication(s) in Google Scholar

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.04%
  • CAS 番号: 557795-19-4
  • 分子式: C22H27FN4O2
  • 分子量:398.47
  • 保管条件:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Sunitinib Chemical Structure
    Sunitinib 構造式
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
  • Experimental Validation Results for Sunitinib
CAS 番号: 557795-19-4
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Sunitinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 Sunitinib

More
Customer Validation & Images
WBRT-PCRIHCCell Proliferation/Viability AssayIF
  • Cell Proliferation/Viability Assay
  • IF
  • WB
  • WB
  • WB
  • IHC
  • WB
  • WB
  • WB
  • WB
  • WB
  • RT-PCR

VEGFR アイソフォーム固有の製品をすべて表示

More

PDGFR アイソフォーム固有の製品をすべて表示

More
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Sunitinib Chemical Structure
    Sunitinib Chemical Structure
    1/16
  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (0-100 μM; 72 h) induces significant cell death in T98G cells.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):514-522. [Abstract]

    Customer Validation
     Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

    Customer Validation
     BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Nov:37:344-355. [Abstract]

    Customer Validation
     Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Western blot analysis of UCP1 protein expression level in mouse brown adipose.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2018 Nov:37:344-355. [Abstract]

    Customer Validation
     Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Representative images of immunohistochemistry stainining of UCP1 in BAT.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118. [Abstract]

    Customer Validation
     In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In 786-O cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In Caki-1 cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72. [Abstract]

    Customer Validation
     Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

  • 1/16

    Sunitinib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

  • Sunitinib